Kamada (KMDA) Total Current Liabilities (2012 - 2026)
Kamada (KMDA) posted quarterly Total Current Liabilities of $59.8 million for Q1 2026, up 4.78% year-on-year from $57.0 million in Q1 2025, and up 26.13% on a QoQ basis from $47.4 million in Q4 2025.
Kamada (KMDA) Total Current Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Total Current Liabilities for 13 consecutive years, with $59.8 million the latest figure, recorded in Q1 2026.
- Quarterly Total Current Liabilities rose 4.78% year-over-year to $59.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.8 million (up 4.78% YoY) and the FY2025 annual result came in at $47.4 million, down 4.04% from the prior year.
- Total Current Liabilities climbed to $59.8 million in Q1 2026 per KMDA's latest filing, from $47.4 million in the prior quarter.
- Over the last five years, Total Current Liabilities for KMDA reached as high as $75.7 million in Q4 2022 and fell as low as $69150.0 in Q3 2022.
- A 5-year average of $43.5 million and a median of $47.4 million in 2025 frame the typical range for Total Current Liabilities.
- The largest YoY upside for Total Current Liabilities was 53800.22% in 2023 against a maximum downside of 99.84% in 2023.
- Year by year, Total Current Liabilities stood at $75.7 million in 2022, then plunged by 34.49% to $49.6 million in 2023, then slipped by 0.41% to $49.4 million in 2024, then decreased by 4.04% to $47.4 million in 2025, then rose by 26.13% to $59.8 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $59.8 million, $47.4 million, and $47.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 59.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.78 Mn |
| Dec 31, 2025 | 47.39 Mn |
| Sep 30, 2025 | 47.84 Mn |
| Jun 30, 2025 | 45.77 Mn |
| Mar 31, 2025 | 57.05 Mn |
| Dec 31, 2024 | 49.39 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 40.90 Mn |
| Mar 31, 2024 | 37.18 Mn |
| Dec 31, 2023 | 49.59 Mn |
| Sep 30, 2023 | 37.27 Mn |
| Jun 30, 2023 | 65.83 Mn |
| Mar 31, 2023 | 69,275.00 |
| Dec 31, 2022 | 75.71 Mn |
| Sep 30, 2022 | 69,150.00 |
| Jun 30, 2022 | 49.68 Mn |
| Mar 31, 2022 | 42.23 Mn |
| Dec 31, 2021 | 54.06 Mn |
| Sep 30, 2021 | 26.59 Mn |
| Jun 30, 2021 | 26.15 Mn |